Elicera Therapeutics AB (publ) (ELIC.ST)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jamal El-Mosleh M.Sc. | CEO & Co-Founder | -- | -- | 1981 |
| Prof. Magnus Essand | Chief Science Officer, Co-Founder & Director | -- | -- | 1964 |
| Mr. Di Yu | Co-Founder & Head of Transitional Research | -- | -- | 1985 |
| Mr. Ingvar Karlsson | Chief Financial Officer | -- | -- | 1956 |
| Ms. Anna Koptina Gultekin | Head of Regulatory Affairs | -- | -- | -- |
Elicera Therapeutics AB (publ)
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 2
Description
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available